Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT02301156 · COMPLETED
Trial details
- NCT number
- NCT02301156
- Sponsor
- TG Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-27
- Primary completion
- 2020-04-01
- Enrollment
- 126
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.